BioNTech's pivotal bispecifics plan take shape
Phase 3 development plans for BNT327 and ivonescimab start to diverge.
BioNTech puts a ring on Biotheus
A year after paying $55m to license Biotheus’s PD-L1/VEGF, BioNTech is going all in for $800m.
Looking for an ivonescimab encore
What similarly acting projects are still unpartnered?
ESMO 2024 movers – VEGF bispecifics win, TIGIT loses
After a conference lacking the wow factor, biotech winners and losers emerge.
One ricochet of the ivonescimab bullet
The small cap biotech Instil Bio tries to follow in Summit’s slipstream.
ESMO 2024 preview – Summit could take on Merck in breast cancer
Early data suggest that PD-(L)1 x VEGF bispecifics might challenge Keytruda in triple-negative disease.
World Lung 2024 – picking apart the Harmoni-2 win
Akeso’s data look impressive, but perhaps not impressive enough to sustain Summit’s valuation.
The month ahead: September’s upcoming events
It’s back to school for biotech, with a packed conference schedule.
